Similar articles

• Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.

  Shah GK, Sang DN, Hughes MS. Shah GK, et al. Retina. 2009 Feb;29(2):133-48. doi: 10.1097/IAE.0b013e3181960a28. Retina. 2009. PMID: 19202423 Review.
• Antiangiogenic therapy in neovascular age-related macular degeneration.

  Lin RC, Rosenfeld PJ. Lin RC, et al. Int Ophthalmol Clin. 2007 Winter;47(1):117-37. doi: 10.1097/IIO.0b013e31802bd873. Int Ophthalmol Clin. 2007. PMID: 17237677 Review. No abstract available.
• Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration.

  Aggio FB, Melo GB, Höfling-Lima AL, Eid Farah M. Aggio FB, et al. Acta Ophthalmol Scand. 2006 Dec;84(6):831-3. doi: 10.1111/j.1600-0420.2006.00764.x. Acta Ophthalmol Scand. 2006. PMID: 17083553 No abstract available.
• Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.

  Kaiser PK; Registry of Visudyne AMD Therapy Writing Committee; Boyer DS, Garcia R, Hao Y, Hughes MS, Jabbour NM, Kaiser PK, Mieler W, Slakter JS, Samuel M, Tolentino MJ, Roth D, Sheidow T, Strong HA. Kaiser PK, et al. Ophthalmology. 2009 Apr;116(4):747-55, 755.e1. doi: 10.1016/j.ophtha.2008.12.057. Epub 2009 Feb 25. Ophthalmology. 2009. PMID: 19243834
• [Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration].

  [No authors listed] [No authors listed] Klin Monbl Augenheilkd. 2007 Jul;224(7):559-66. doi: 10.1055/s-2007-963356. Klin Monbl Augenheilkd. 2007. PMID: 17657689 German.